T. Andrew Crockett
2023
In 2023, T. Andrew Crockett earned a total compensation of $3.6M as Chief Executive Officer at Carbylan Therapeutics, a 44% decrease compared to previous year.
Compensation breakdown
| Bonus | $266,805 |
|---|---|
| Option Awards | $454,610 |
| Salary | $635,200 |
| Stock Awards | $2,265,714 |
| Other | $12,603 |
| Total | $3,634,983 |
Crockett received $2.3M in stock awards, accounting for 62% of the total pay in 2023.
Crockett also received $266.8K in bonus, $454.6K in option awards, $635.2K in salary and $12.6K in other compensation.
Rankings
In 2023, T. Andrew Crockett's compensation ranked 222nd out of 2,983 executives tracked by ExecPay. In other words, Crockett earned more than 92.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 222 out of 2,983 | 93rd |
Division Manufacturing | 119 out of 1,637 | 93rd |
Major group Chemicals And Allied Products | 80 out of 906 | 91st |
Industry group Drugs | 78 out of 869 | 91st |
Industry Pharmaceutical Preparations | 48 out of 627 | 92nd |
Source: SEC filing on August 14, 2023.
Crockett's colleagues
We found two more compensation records of executives who worked with T. Andrew Crockett at Carbylan Therapeutics in 2023.